BR112017018944A2 - método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) - Google Patents
método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)Info
- Publication number
- BR112017018944A2 BR112017018944A2 BR112017018944A BR112017018944A BR112017018944A2 BR 112017018944 A2 BR112017018944 A2 BR 112017018944A2 BR 112017018944 A BR112017018944 A BR 112017018944A BR 112017018944 A BR112017018944 A BR 112017018944A BR 112017018944 A2 BR112017018944 A2 BR 112017018944A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbinoid
- drug
- treating
- condition
- disease state
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562126757P | 2015-03-02 | 2015-03-02 | |
US201662299260P | 2016-02-24 | 2016-02-24 | |
PCT/US2016/020446 WO2016141056A1 (en) | 2015-03-02 | 2016-03-02 | Topical regional neuro-affective therapy with cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017018944A2 true BR112017018944A2 (pt) | 2018-05-15 |
Family
ID=56849015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017018944A BR112017018944A2 (pt) | 2015-03-02 | 2016-03-02 | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
Country Status (11)
Country | Link |
---|---|
US (4) | US20160256410A1 (pt) |
EP (1) | EP3265081A4 (pt) |
JP (1) | JP2018507262A (pt) |
CN (1) | CN107530318A (pt) |
AU (1) | AU2016226267A1 (pt) |
BR (1) | BR112017018944A2 (pt) |
CA (1) | CA2978605A1 (pt) |
HK (2) | HK1244715A1 (pt) |
IL (1) | IL254294A0 (pt) |
MX (1) | MX2017011280A (pt) |
WO (1) | WO2016141056A1 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
CN107951869A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 含有大麻二酚的药物制剂及其应用 |
CN107952075A (zh) * | 2016-10-14 | 2018-04-24 | 汉义生物科技(北京)有限公司 | 一种含大麻二酚的组合物及其应用 |
CN108079305A (zh) * | 2016-11-23 | 2018-05-29 | 汉义生物科技(北京)有限公司 | 大麻二酚与三环类抗抑郁药的药物组合物及其用途 |
CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技(北京)有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
EP3488220A4 (en) * | 2016-11-29 | 2020-03-04 | Axim Biotechnologies, Inc. | CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE |
CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技(北京)有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
EP3558297A1 (en) * | 2016-12-20 | 2019-10-30 | Tilray, Inc. | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
US20220323401A1 (en) * | 2017-02-15 | 2022-10-13 | Botanix Pharmaceuticals Ltd. | Formulations of cannabinoids for the treatment of acne |
US20210401768A1 (en) * | 2017-02-15 | 2021-12-30 | Botanix Pharmaceuticals Ltd. | Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
US20210115748A9 (en) * | 2017-03-27 | 2021-04-22 | Patagonia Pharmaceuticals Llc | Topical compositions and methods of treatment |
CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
JOP20200082A1 (ar) | 2017-09-28 | 2020-04-30 | Zynerba Pharmaceuticals Inc | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
WO2019135224A1 (en) * | 2018-01-03 | 2019-07-11 | Icdpharma Ltd. | Taste-enhanced cannabinoid submicron emulsion syrup compositions |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
CN111936126A (zh) * | 2018-01-24 | 2020-11-13 | 博塔尼克斯制药有限公司 | 用于皮炎和炎症性皮肤病的大麻素给药方案 |
AU2019210704A1 (en) * | 2018-01-24 | 2020-08-06 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for psoriasis |
CA3089346A1 (en) * | 2018-01-24 | 2019-08-01 | Botanix Pharmaceuticals Ltd | Cannabinoid dosing regime for acne |
BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
CA3095873A1 (en) * | 2018-04-05 | 2019-10-10 | Steven Robert ERBST | Therapeutic elastic bandage for modulating the endocannabinoid system |
AU2019251357B2 (en) | 2018-04-09 | 2023-10-05 | Portland Technology Holdings Llc | Hemp extract for treatment of pain in animals |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US10668045B2 (en) * | 2018-07-12 | 2020-06-02 | Bright Green Corporation | Topical massage oil and cream containing CBD, CBN, curcumin and Boswellia resin |
US20210322312A1 (en) * | 2018-08-17 | 2021-10-21 | Kirsten K. Shepard | Cannabidiol composition and methods thereof |
US10588979B1 (en) * | 2018-09-17 | 2020-03-17 | Cody D. Freeze | Cannabinoid and terpene-infused topical cream |
WO2020079686A1 (en) * | 2018-10-15 | 2020-04-23 | Vardi Amnon | Slow release cannabinoids and products thereof |
EP3643303A1 (en) * | 2018-10-22 | 2020-04-29 | InnovativeHealth Group SL | Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof |
US20200181051A1 (en) * | 2018-12-07 | 2020-06-11 | Jeffrey Alan McKinney | Deuterated agonists and methods of use |
AU2019396750A1 (en) | 2018-12-14 | 2021-07-08 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
JP7303969B2 (ja) * | 2019-01-08 | 2023-07-06 | 株式会社ワンインチ | 電子タバコ用液体組成物及びそれを有する電子タバコ |
US20200254271A1 (en) * | 2019-02-13 | 2020-08-13 | Chiscan Holdings, Llc | Devices and methods for application of non-thermal plasma |
CN109718229B (zh) * | 2019-02-15 | 2021-05-28 | 烟台汉麻生物技术有限公司 | 一种抗炎药物组合物及其应用 |
US11752127B2 (en) | 2019-04-01 | 2023-09-12 | Virbac Corporation | Methods and compositions for treatment of anxiety in animals |
US20200352826A1 (en) * | 2019-05-06 | 2020-11-12 | Atomic Health, Inc. | Systems And Methods For Manufacturing Cannabis Edibles, And Resulting Edible Products |
CA3141993A1 (en) * | 2019-05-28 | 2020-12-03 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US20220378718A1 (en) * | 2019-05-28 | 2022-12-01 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
EP3990024B1 (fr) * | 2019-06-25 | 2023-06-21 | AB7 Santé | Dispositif sous forme de matrice polymere a base de cannabinoïdes |
BR112021026374A2 (pt) * | 2019-06-26 | 2022-06-07 | Cannpal Animal Therapeutics Ltd | Composição de cbd |
US10588871B1 (en) | 2019-06-28 | 2020-03-17 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
WO2021016236A1 (en) * | 2019-07-22 | 2021-01-28 | Novilla Pharmaceuticals, Inc. | Method of remotely controlling pain |
CA3147357A1 (en) * | 2019-08-21 | 2021-02-25 | Stephen Goldner | Medical apparatus with cannabis sativa l. |
AU2020348310A1 (en) * | 2019-09-17 | 2022-03-31 | Zynerba Pharmaceuticals, Inc. | Treatment of behavioral impairment in developmental and epileptic encephalopathy |
US20220347096A1 (en) | 2019-10-03 | 2022-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal cannabinoids and uses thereof |
EP4041209A4 (en) * | 2019-10-11 | 2024-01-24 | Pike Therapeutics Inc | TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS |
US20210251918A1 (en) * | 2019-10-11 | 2021-08-19 | Pike Therapeutics Inc., 1219014 B.C. Ltd | Pharmaceutical composition and method for treating seizure disorders |
IL292775A (en) * | 2019-11-08 | 2022-07-01 | Vella Bioscience Inc | preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders |
MX2022007019A (es) * | 2019-12-09 | 2022-08-15 | Nicoventures Trading Ltd | Producto oral que contiene un canabinoide. |
US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
WO2021188865A1 (en) * | 2020-03-19 | 2021-09-23 | New York Medical College | Cannabinoid medical carrier |
JP2023523155A (ja) * | 2020-04-20 | 2023-06-02 | パイク セラピューティクス,インコーポレイテッド | 慢性疼痛治療のためのカンナビジオール及び/又はテトラヒドロカンナビノールを含有する経皮製剤及び/又は局所製剤 |
AU2021322987A1 (en) * | 2020-08-03 | 2023-03-09 | SciSparc Ltd. | Methods for maintaining microvascular integrity |
CA3187582A1 (en) * | 2020-08-17 | 2022-02-24 | Fotios M. Plakogiannis | Pharmaceutical compositions and methods for treating parkinson's disease |
US20220054446A1 (en) * | 2020-08-18 | 2022-02-24 | Yvette Rose Webb | Targeted treatment with a topical cream of cannabinoids, terpenes, and essential oils |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
WO2022159506A1 (en) * | 2021-01-19 | 2022-07-28 | Merit Therapeutics, Inc. | Deuterated cannabidiol compounds |
WO2022215030A1 (en) * | 2021-04-08 | 2022-10-13 | Pike Therapeutics Inc., 1219014 B.C. Ltd | Pharmaceutical composition and method for treating seizure disorders |
EP4326251A1 (en) * | 2021-04-19 | 2024-02-28 | Symrise AG | Compositions comprising cannabidiol and, optionally, bisabolol |
CA3217153A1 (en) * | 2021-04-30 | 2022-11-03 | Philip E. Wolfson | Ketamine and cannabis for the treatment of emotional disorders |
CN116159045B (zh) * | 2021-11-24 | 2024-03-19 | 四川大学华西医院 | 大麻二酚和/或次大麻二酚在制备局部麻醉药药效增强剂中的应用 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4767619A (en) | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
GR79215B (pt) | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
US4511563A (en) | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US5364628A (en) | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
GB8419575D0 (en) | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5016652A (en) | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DE3710216A1 (de) | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
GB2208646B (en) | 1987-08-13 | 1991-06-26 | Glaxo Group Ltd | Indole derivatives |
US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
IL98392A (en) | 1990-06-07 | 1996-01-19 | Wellcome Found | History of indole, their preparation and the pharmaceutical preparations containing them |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
RU2095360C1 (ru) | 1990-10-15 | 1997-11-10 | Пфайзер Инк. | Производные индола, их оптические изомеры и фармацевтически приемлемые соли |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
GB9103770D0 (en) | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
DE4314976C1 (de) | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5807571A (en) | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
WO1995005137A1 (en) | 1993-08-16 | 1995-02-23 | Cygnus Therapeutic Systems | Transdermal delivery system using a combination of permeation enhancers |
KR960015375B1 (ko) | 1994-06-08 | 1996-11-11 | 현대전자산업 주식회사 | 강유전체 박막 제조장치 및 그를 사용한 강유전체 박막 제조방법 |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
ATE334689T1 (de) | 1995-11-13 | 2006-08-15 | Univ Northwest | Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe |
US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US5872145A (en) | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
ES2234324T3 (es) | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6203796B1 (en) | 1999-07-08 | 2001-03-20 | Andreas D. Papaprodromou | Oregano-based therapeutic composition |
SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20020165207A1 (en) | 2001-05-02 | 2002-11-07 | Richard Rosenbloom | Compositions and methods for the treatment of diabetic neuropathy |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
JP2005504717A (ja) | 2001-01-16 | 2005-02-17 | パーデュー・リサーチ・ファウンデーション | ドーパミン関連性機能不全の治療法 |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
ES2312585T3 (es) | 2001-06-05 | 2009-03-01 | Ronald Aung-Din | Terapia contra la migraña por via topica. |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US20030167556A1 (en) | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
WO2005000086A2 (en) | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
US8263574B2 (en) * | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
CA2577219A1 (en) | 2004-10-01 | 2006-04-13 | Ache Laboratorios Farmaceuticos S.A. | Use of caryophyllenes in the manufacture of medicaments and treatment of bodily conditions of inflammation and inflammatory pain |
CA2650853A1 (en) | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
WO2010005507A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
CN102223791A (zh) | 2008-09-27 | 2011-10-19 | 塔阿克斯有限公司 | 用于神经病变治疗的局部用制剂 |
CA2760460C (en) * | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
AU2009345154A1 (en) | 2009-04-29 | 2011-12-22 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
HUE026929T2 (en) | 2010-10-19 | 2016-08-29 | Parenteral A S | Composition for treating inflammatory diseases comprising boswellic acids and cannabidol |
US20140030289A1 (en) | 2011-02-06 | 2014-01-30 | Rivka Ofir | Compositions comprising beta-caryophyllene and methods of utilizing the same |
WO2013009928A1 (en) * | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
US20150051299A1 (en) | 2012-03-19 | 2015-02-19 | Ariel-University Research And Development Company, Ltd. | Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists |
US9345659B2 (en) | 2012-12-11 | 2016-05-24 | Avon Products, Inc. | Use of melicope extracts to improve conditions caused by excess lipids |
US9580400B2 (en) * | 2013-02-26 | 2017-02-28 | Northeastern University | Cannabinergic nitrate esters and related analogs |
WO2015068052A2 (en) | 2013-10-31 | 2015-05-14 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
WO2016014419A1 (en) | 2014-07-21 | 2016-01-28 | Glia, Llc | Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
CA2979184C (en) * | 2015-03-10 | 2020-09-08 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
-
2016
- 2016-03-02 BR BR112017018944A patent/BR112017018944A2/pt not_active IP Right Cessation
- 2016-03-02 US US15/058,859 patent/US20160256410A1/en not_active Abandoned
- 2016-03-02 MX MX2017011280A patent/MX2017011280A/es unknown
- 2016-03-02 EP EP16759411.8A patent/EP3265081A4/en not_active Withdrawn
- 2016-03-02 CA CA2978605A patent/CA2978605A1/en not_active Abandoned
- 2016-03-02 WO PCT/US2016/020446 patent/WO2016141056A1/en active Application Filing
- 2016-03-02 CN CN201680025420.2A patent/CN107530318A/zh active Pending
- 2016-03-02 US US15/058,946 patent/US10716766B2/en active Active
- 2016-03-02 JP JP2017565040A patent/JP2018507262A/ja active Pending
- 2016-03-02 AU AU2016226267A patent/AU2016226267A1/en not_active Abandoned
-
2017
- 2017-06-02 US US15/612,375 patent/US20170266128A1/en not_active Abandoned
- 2017-09-03 IL IL254294A patent/IL254294A0/en unknown
-
2018
- 2018-04-03 HK HK18104400.6A patent/HK1244715A1/zh unknown
- 2018-06-28 HK HK18108330.2A patent/HK1248564A1/zh unknown
- 2018-07-12 US US16/033,899 patent/US10172809B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20170266128A1 (en) | 2017-09-21 |
MX2017011280A (es) | 2018-06-27 |
US20160256411A1 (en) | 2016-09-08 |
CA2978605A1 (en) | 2016-09-09 |
JP2018507262A (ja) | 2018-03-15 |
US10716766B2 (en) | 2020-07-21 |
WO2016141056A1 (en) | 2016-09-09 |
EP3265081A1 (en) | 2018-01-10 |
US20180318237A1 (en) | 2018-11-08 |
US10172809B2 (en) | 2019-01-08 |
HK1244715A1 (zh) | 2018-08-17 |
US20160256410A1 (en) | 2016-09-08 |
CN107530318A (zh) | 2018-01-02 |
AU2016226267A1 (en) | 2017-09-28 |
HK1248564A1 (zh) | 2018-10-19 |
IL254294A0 (en) | 2017-10-31 |
EP3265081A4 (en) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017018944A2 (pt) | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) | |
IL281566A (en) | Methods and systems for diagnosing and treating diseases | |
ZA201802351B (en) | Electrode system, device and method for the treatment of eye diseases, in particular dry eye | |
KR20180084980A (ko) | 진단 장치, 컴퓨터 프로그램, 및 진단 시스템 | |
BR112017015614A2 (pt) | produtos terapêuticos de glicano e métodos relacionados dos mesmos. | |
DK3472455T3 (da) | Kontrol- eller behandlingssystem og fremgangsmåde | |
IL264301A (en) | Treatment of Fabry disease in ert-naive and ert-experienced patients | |
BR112015007758A2 (pt) | dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho. | |
BR112017002074A2 (pt) | vestuário e método de compressão médica terapêutica | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
BR112015031471A2 (pt) | método e sistema de inspeção de segurança do corpo humano. | |
EP3398633A4 (en) | ADMINISTRATION DEVICE DESIGN SYSTEM, ADMINISTRATION SYSTEM, ADMINISTRATION DEVICE DESIGN METHOD, ADMINISTRATION DEVICE DESIGN PROGRAM, AND MEDICAL DEVICE DESIGN SYSTEM | |
IL269083A (en) | Methods for the prevention and treatment of heart diseases | |
SG11201703202YA (en) | Method and system for detection of disease agents in blood | |
ZA201800037B (en) | Diagnosis and treatment of infectious disease | |
SG11201800235RA (en) | Patient status determination device, patient status determination method and program | |
MA49633A (fr) | Agents, utilisations et procédés de traitement | |
DK2834643T3 (da) | Fremgangsmåde til behandling af blod, blodprodukter og organer | |
SG11201705426VA (en) | System and method for adjusting the blood glucose level of a person | |
ITUA20163417A1 (it) | Fat and medical uses thereof | |
EP3342864A4 (en) | DIAGNOSTIC PROCEDURE FOR AUTOIMMUNE DISEASES, BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES AND ACTIVE AGGREGATE FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | |
MA50358A (fr) | Sémaglutide en thérapie médicale | |
BR112014032290A2 (pt) | composições e métodos para tratar ou prevenir infecção de pneumovírus e doenças associadas. | |
DK3641795T3 (da) | Methods and materials for treating blood vessels | |
EP3554615C0 (de) | Vorrichtung zur human- und tiermedizinischen behandlung und applikationseinrichtung dafür |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2620 DE 23/03/2021. |